Passive immunotherapy of cancer in animals and man.
Publisher Summary Immunologic manipulations to control tumor growth can essentially be divided into passive and active categories. Passive immunotherapy refers to approaches in which immunologic reagents, such as serum, cells, or cell products that are thought to have antitumor activity, are administered to a tumor-bearing host. This chapter reviews recent studies of the use of passive immunotherapy for the treatment of cancer in animals and man. Immune depression in cancer patients has been well documented and attempts to actively stimulate both nonspecific and specific antitumor immune reactions in cancer patients is generally let down by intrinsic defects in the ability of the host to respond. The passive administration of immune reagents can be capable of reacting against the tumor independent of the host's immune competence. Therefore, passive therapy is regarded as an attractive area of investigation in tumor immunotherapy. The chapter summarizes the existing information concerning the use of subcellular products, such as immune RNA or transfer factor, in the treatment of animal and human malignancy. It is noted that because of immunodepression caused by cancer treatments, passive immunotherapy is considered independent of host immune competence, and is therefore an ideal candidate for inclusion in combined-modality approaches to cancer therapy.